Arrhythmic Complications of Tyrosine Kinase Inhibitors

References

• Lal H , KolajaKL, ForceT . Cancer genetics and the cardiotoxicity of the therapeutics . J. Am. Coll. Cardiol.61 ( 3 ), 267 – 274 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Krause DS , Van EttenRA . Tyrosine kinases as targets for cancer therapy . N. Engl. J. Med.353 ( 2 ), 172 – 187 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hasinoff BB . The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity . Toxicol. Appl. Pharmacol.244 ( 2 ), 190 – 195 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tamargo J , CaballeroR, DelponE . Cancer chemotherapy and cardiac arrhythmias: a review . Drug Saf.38 ( 2 ), 129 – 152 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Curigliano G , SpitaleriG, FingertHJet al. Drug-induced qtc interval prolongation: a proposal towards an efficient and safe anticancer drug development . Eur. J. Cancer44 ( 4 ), 494 – 500 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Shah RR , MorganrothJ, ShahDR . Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval) . Drug Saf.36 ( 5 ), 295 – 316 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Strevel EL , IngDJ, SiuLL . Molecularly targeted oncology therapeutics and prolongation of the QT interval . J. Clin. Oncol.25 ( 22 ), 3362 – 3371 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Chu TF , RupnickMA, KerkelaRet al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib . Lancet370 ( 9604 ), 2011 – 2019 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Zang J , WuS, TangLet al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis . PLoS One7 ( 2 ), e30353 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Locatelli M , CriscitielloC, EspositoAet al. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review . Target Oncol.10 ( 1 ), 27 – 43 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Tam CS , KantarjianH, Garcia-ManeroGet al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia . Blood112 ( 3 ), 516 – 518 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zhang DY , WangY, LauCP, TseHF, LiGR . Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels . Cell Signal.20 ( 10 ), 1815 – 1821 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lu Z , WuCY, JiangYPet al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome . Sci. Transl. Med.4 ( 131 ), 131ra150 ( 2012 ).
   Web of Science ®Google Scholar
• Yang T , ChunYW, StroudDMet al. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current . Circulation130 ( 3 ), 224 – 234 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rutledge CA , NgFS, SulkinMSet al. c-Src kinase inhibition reduces arrhythmia inducibility and connexin43 dysregulation after myocardial infarction . J. Am. Coll. Cardiol.63 ( 9 ), 928 – 934 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Morgan TK Jr. , SullivanME . An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy . Prog. Med. Chem.29, 65 – 108 ( 1992 ).
   PubMedGoogle Scholar
• Go AS , MozaffarianD, RogerVLet al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association . Circulation127 ( 1 ), e6 – e245 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• O’neal WT , LakoskiSG, QureshiWet al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study) . Am. J. Cardiol.115 ( 8 ), 1090 – 1094 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Farmakis D , ParissisJ, FilippatosG . Insights into onco-cardiology: atrial fibrillation in cancer . J. Am. Coll. Cardiol.63 ( 10 ), 945 – 953 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mego M , ReckovaM, ObertovaJ, Sycova-MilaZ, BrozmanovaK, MardiakJ . Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma . Ann. Oncol.18 ( 11 ), 1906 – 1907 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Xu Z , CangS, YangT, LiuD . Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia thereapy . Hematol. Rev.1 ( e4 ), 17 – 21 ( 2009 ).
   Google Scholar
• Wang ML , RuleS, MartinPet al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma . N. Engl. J. Med.369 ( 6 ), 507 – 516 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Byrd JC , BrownJR, O’brienSet al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia . N. Engl. J. Med.371 ( 3 ), 213 – 223 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pretorius L , DuXJ, WoodcockEAet al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation . Am. J. Pathol.175 ( 3 ), 998 – 1009 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chong E , ChangSL, HsiaoYWet al. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation . Heart Rhythm12 ( 5 ), 1046 – 1056 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Singhal R , ChangSL, ChongEet al. Colchicine suppresses atrial fibrillation in failing heart . Int. J. Cardiol.176 ( 3 ), 651 – 660 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Craxton A , JiangAM, KurosakiT, ClarkEA . Syk and Bruton’s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt . J. Biol. Chem.274 ( 43 ), 30644 – 30650 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Mcmullen JR , BoeyEJ, OoiJY, SeymourJF, KeatingMJ, TamCS . Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac pi3k-akt signaling . Blood124 ( 25 ), 3829 – 3830 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Furman RR , SharmanJP, CoutreSEet al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia . N. Engl. J. Med.370 ( 11 ), 997 – 1007 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gopal AK , KahlBS, De VosSet al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma . N. Engl. J. Med.370 ( 11 ), 1008 – 1018 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lannutti BJ , MeadowsSA, HermanSEet al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability . Blood117 ( 2 ), 591 – 594 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Davis RE , NgoVN, LenzGet al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma . Nature463 ( 7277 ), 88 – 92 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wiestner A . Targeting B-Cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies . J. Clin. Oncol.31 ( 1 ), 128 – 130 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yang T , YangP, RodenDM, DarbarD . Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation . Heart Rhythm7 ( 9 ), 1246 – 1252 ( 2010 ).
   PubMed Web of Science ®Google Scholar